Biopharmaceutical industry is incorporating biomarker concepts throughout the R&D processes, including the inclusion of biomarker-related data in the submission of new drug applications. In this paper we discuss the role of IT and information systems that support incorporation of surrogate biomarkers in the clinical development process, with emphasis on new molecular imaging technologies and associated IT requirements. In addition, we discuss how recently introduced FDA standards regarding submission data and FDA guidance documents related to genomic and imaging data can be accommodated in a solution architecture for (surrogate) biomarker-based clinical development.
View Article and Find Full Text PDFDrug Discov Today
June 2002
Text literature is playing an increasingly important role in biomedical discovery. The challenge is to manage the increasing volume, complexity and specialization of knowledge expressed in this literature. Although information retrieval or text searching is useful, it is not sufficient to find specific facts and relations.
View Article and Find Full Text PDF